Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin. However, the mechanisms that mediate the IFN-I-stimulated immune responses against UC have yet to be eluci...

Full description

Bibliographic Details
Main Authors: Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R. Parker, Seppo Yla-Herttuala, SUO CTC Bladder Committee, David McConkey, Kimberly S. Schluns, Colin P. Dinney
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:OncoImmunology
Subjects:
pd-1
interferon
bladder cancer
immune microenvironment
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1577125

Internet

http://dx.doi.org/10.1080/2162402X.2019.1577125

Similar Items